These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 10863323)

  • 1. [Therapy of advanced stages. "Mega-HAART" or "drug holiday"?].
    MMW Fortschr Med; 2000 Mar; 142 Suppl 1():86-7. PubMed ID: 10863323
    [No Abstract]   [Full Text] [Related]  

  • 2. [Resistance screening].
    Sierra S; Lengauer T; Kaiser R
    MMW Fortschr Med; 2009 Apr; 151(18):72, 74-5. PubMed ID: 19769083
    [No Abstract]   [Full Text] [Related]  

  • 3. [Integrase inhibition].
    Bogner JR
    MMW Fortschr Med; 2009 Apr; 151(18):68-71. PubMed ID: 19769082
    [No Abstract]   [Full Text] [Related]  

  • 4. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multidrug-resistant HIV-1.
    Tayloe D
    Clin Infect Dis; 2004 May; 38(10):1507; author reply 1507. PubMed ID: 15156500
    [No Abstract]   [Full Text] [Related]  

  • 6. Virological and pharmacological factors associated with virological response to salvage therapy after an 8-week of treatment interruption in a context of very advanced HIV disease (GigHAART ANRS 097).
    Delaugerre C; Peytavin G; Dominguez S; Marcelin AG; Duvivier C; Gourlain K; Amellal B; Legrand M; Raffi F; Costagliola D; Katlama C; Calvez V
    J Med Virol; 2005 Nov; 77(3):345-50. PubMed ID: 16173015
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Improved long-term success. New nucleoside for once daily combinations].
    MMW Fortschr Med; 2004 Apr; 146 Spec No 1():31-3. PubMed ID: 15373043
    [No Abstract]   [Full Text] [Related]  

  • 8. [How HIV treatment can be simplified. "Once daily" as starter therapy is effective].
    Wepner U
    MMW Fortschr Med; 2009 Apr; 151(18):80-1. PubMed ID: 19769085
    [No Abstract]   [Full Text] [Related]  

  • 9. Adherence to antiretroviral therapy: how much is enough?
    Gulick RM
    Clin Infect Dis; 2006 Oct; 43(7):942-4. PubMed ID: 16941381
    [No Abstract]   [Full Text] [Related]  

  • 10. [HIV-infection: modern antiretroviral therapy].
    Rockstroh JK; Spengler U
    Dtsch Med Wochenschr; 2004 Sep; 129(37):1921-4. PubMed ID: 15372371
    [No Abstract]   [Full Text] [Related]  

  • 11. Dynamics and evolution of HIV-1 during structured treatment interruptions.
    Frost SD
    AIDS Rev; 2002; 4(3):119-27. PubMed ID: 12416446
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Highly active initial therapy without resistance development. Even after 6 years still effective HIV therapy].
    MMW Fortschr Med; 2005 Apr; 147 Spec No 1():54-5. PubMed ID: 16385876
    [No Abstract]   [Full Text] [Related]  

  • 13. Response to HAART in French patients with resistant HIV-1 treated at primary infection: ANRS Resistance Network.
    Chaix ML; Desquilbet L; Descamps D; Costagliola D; Deveau C; Galimand J; Goujard C; Signori-Schmuck A; Schneider V; Tamalet C; Pellegrin I; Wirden M; Masquelier B; Brun-Vezinet F; Rouzioux C; Meyer L; ;
    Antivir Ther; 2007; 12(8):1305-10. PubMed ID: 18240870
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Antiretroviral therapy. Simpler and more tolerable with equally high effectiveness].
    MMW Fortschr Med; 2005 Apr; 147 Spec No 1():78-9. PubMed ID: 16385885
    [No Abstract]   [Full Text] [Related]  

  • 15. Treatment interruptions in HIV-infected subjects.
    Bongiovanni M; Casana M; Tincati C; d'Arminio Monforte A
    J Antimicrob Chemother; 2006 Sep; 58(3):502-5. PubMed ID: 16816398
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Resistance test welcomed, with caution.
    AIDS Alert; 1997 Oct; 12(10):113-5. PubMed ID: 11364716
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Reactions to the New York "supervirus". A challenge in primary resistance].
    Paukstadt W
    MMW Fortschr Med; 2005 Apr; 147 Spec No 1():86. PubMed ID: 16385890
    [No Abstract]   [Full Text] [Related]  

  • 18. Development of HIV with drug resistance after CD4 cell count-guided structured treatment interruptions in patients treated with highly active antiretroviral therapy after dual-nucleoside analogue treatment.
    Nuesch R; Ananworanich J; Sirivichayakul S; Ubolyam S; Siangphoe U; Hill A; Cooper D; Lange J; Phanuphak P; Ruxrungtham K
    Clin Infect Dis; 2005 Mar; 40(5):728-34. PubMed ID: 15714420
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Managing antiretroviral therapy: changing regimens, resistance testing, and the risks from structured treatment interruptions.
    Eron JJ
    J Infect Dis; 2008 May; 197 Suppl 3():S261-71. PubMed ID: 18447612
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunovirologic consequences and safety of short, non-structured interruptions of successful antiretroviral treatment.
    Sanchez R; Portilla J; Gimeno A; Boix V; Llopis C; Sanchez-Paya J; Merino E; de la Sen ML; Muñoz C; Reus S; Plazas J
    J Infect; 2007 Feb; 54(2):159-66. PubMed ID: 16690132
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.